PMID- 31841646
OWN - NLM
STAT- MEDLINE
DCOM- 20210610
LR  - 20210610
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 30
IP  - 3
DP  - 2020 Apr
TI  - Pre-Existing Comorbid Emotional Symptoms Moderate Short-Term Methylphenidate 
      Adverse Effects in a Randomized Trial of Children with 
      Attention-Deficit/Hyperactivity Disorder.
PG  - 137-147
LID - 10.1089/cap.2019.0125 [doi]
AB  - Objective: We sought to ascertain whether baseline anxiety/depression and 
      oppositional defiant disorder (ODD) symptoms impacted the experience of 
      short-term methylphenidate (MPH) adverse effects (AEs) in 7- to 11-year-old 
      children with attention-deficit/hyperactivity disorder (ADHD) (n = 171) 
      undergoing a double-blind MPH crossover trial. Method: The Vanderbilt ADHD 
      Diagnostic Parent Rating Scale measured baseline child anxiety/depression and ODD 
      symptomology. The parent-completed Pittsburgh Side Effect Rating Scale assessed 
      the AEs of anxiety, sadness, and irritability at baseline, on placebo, and on 
      three MPH dosages. For each AE, we evaluated comorbidity main effects, dose main 
      effects, and comorbidity x dose interactions. Results: Baseline 
      anxiety/depression x dose and ODD x dose interactions were significant for the 
      AEs of anxiety, sadness, and irritability. Compared with premedication baseline, 
      these AEs attenuated on MPH for children with initially higher comorbidity 
      symptoms, whereas those with initially lower comorbidity symptoms tended toward 
      no change or increasing AE levels. Conclusion: Premedication anxiety/depressive 
      and ODD symptoms may be important predictors of short-term MPH emotional AEs.
FAU - Froehlich, Tanya E
AU  - Froehlich TE
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio.
FAU - Brinkman, William B
AU  - Brinkman WB
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio.
FAU - Peugh, James L
AU  - Peugh JL
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio.
FAU - Piedra, Alexandra N
AU  - Piedra AN
AD  - Department of Psychology, Case Western Reserve University, Cleveland, Ohio.
FAU - Vitucci, Daniel J
AU  - Vitucci DJ
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio.
FAU - Epstein, Jeffery N
AU  - Epstein JN
AD  - Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 
      University of Cincinnati College of Medicine, Cincinnati, Ohio.
LA  - eng
GR  - R01 MH074770/MH/NIMH NIH HHS/United States
GR  - K23 MH083881/MH/NIMH NIH HHS/United States
GR  - K24 MH064478/MH/NIMH NIH HHS/United States
GR  - K23 MH083027/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
DEP - 20191216
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Central Nervous System Stimulants)
RN  - 207ZZ9QZ49 (Methylphenidate)
SB  - IM
MH  - Anxiety/epidemiology
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology
MH  - Attention Deficit and Disruptive Behavior Disorders/*drug therapy
MH  - Central Nervous System Stimulants/administration & dosage/*adverse effects
MH  - Child
MH  - Cross-Over Studies
MH  - Depression/epidemiology
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Methylphenidate/administration & dosage/*adverse effects
PMC - PMC7153644
OTO - NOTNLM
OT  - ADHD
OT  - adverse effects
OT  - methylphenidate
OT  - side effects
OT  - stimulants
COIS- Dr. Epstein has received research support from Akili Interactive Labs, received 
      royalties from Multi-Health Systems, Inc., received consulting fees from the 
      American Academy of Pediatrics and American Board of Pediatrics, and received 
      licensing fees from Optimal Medicine, Inc. and IXICO. Dr. Froehlich, Dr. 
      Brinkman, Dr. Peugh, Ms. Piedra, and Mr. Vitucci have no conflicts of interest or 
      financial disclosures.
EDAT- 2019/12/17 06:00
MHDA- 2021/06/11 06:00
PMCR- 2021/04/01
CRDT- 2019/12/17 06:00
PHST- 2019/12/17 06:00 [pubmed]
PHST- 2021/06/11 06:00 [medline]
PHST- 2019/12/17 06:00 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 10.1089/cap.2019.0125 [pii]
AID - 10.1089/cap.2019.0125 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2020 Apr;30(3):137-147. doi: 
      10.1089/cap.2019.0125. Epub 2019 Dec 16.